Pharmadrug Inc. PHRX
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.93% | -3.81% | 277.60% | -55.17% | -64.71% |
| Depreciation & Amortization | 0.00% | 4.55% | 0.00% | -1.09% | -1.09% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.97% | -1.85% | -16.75% | -47.44% | 752.94% |
| Operating Income | -8.97% | 1.85% | 16.75% | 47.44% | -752.94% |
| Income Before Tax | -194.45% | -75.74% | -1,958.00% | 52.30% | 41.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -194.45% | -75.74% | -1,958.00% | 52.30% | 41.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -50.00% | -38.14% | -23.40% | 1.41% | -7.37% |
| Net Income | -235.43% | -94.99% | -2,325.58% | 55.41% | 45.20% |
| EBIT | -8.97% | 1.85% | 16.75% | 47.44% | -752.94% |
| EBITDA | -25.93% | 3.81% | 18.45% | 62.72% | -172.00% |
| EPS Basic | -160.00% | -66.67% | -- | 58.33% | 50.00% |
| Normalized Basic EPS | -166.67% | -50.00% | -233.33% | 57.14% | 50.00% |
| EPS Diluted | -160.00% | -66.67% | -- | 58.33% | 50.00% |
| Normalized Diluted EPS | -166.67% | -50.00% | -233.33% | 57.14% | 50.00% |
| Average Basic Shares Outstanding | 24.00% | 24.54% | 0.44% | 3.93% | 7.82% |
| Average Diluted Shares Outstanding | 24.00% | 24.54% | 0.44% | 3.93% | 7.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |